Literature DB >> 15126338

Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma.

Yuh-Shan Jou1, Chih-Shia Lee, Ya-Hui Chang, Chin-Fu Hsiao, Chian-Feng Chen, Chuan-Chuan Chao, Lawrence S H Wu, Shiou-Hwei Yeh, Ding-Shinn Chen, Pei-Jer Chen.   

Abstract

Systematic scan and statistical analysis of loss of heterozygosity (LOH) has been widely used to define chromosomal aberrations in various cancers for cloning of tumor suppressor genes and for development of prognostic markers. However, the establishment of novel strategies is needed, so that the nonrandom but heterogeneous chromosomal aberration data could provide significant insights into our understanding of molecular pathogenesis of cancers. After comprehensive allelotyping of recurrent allelic losses with 441 highly informative microsatellite markers and overlapping LOH regions on human hepatocellular carcinoma (HCC) chromosomes, 33 minimal deleted regions (MDRs) were revealed. Five and 15 of the 33 MDRs have physical intervals in less than 5 and 10 Mb, respectively, with the smallest MDR9p1 of 2.2 Mb located at 9p21.3-p21.2. Statistical and Kaplan-Meier survival analysis revealed a significant association between the loss of MDR15q1 (15q21.1-q22.2) and the HCC patient survival (adjusted P = 0.033). After cluster analysis of 33 MDRs that represented LOH profiles of each HCC tissue based on clinicopathological features and p53 mutations, two major genetic pathways, low-stage and advanced-stage HCC, were uncovered based on high concordance of MDR clusters. We propose that the definition of genome-wide MDRs on the cancer genome not only narrows down the location of existing tumor suppressor genes to facilitate positional candidate cloning and develop potential prognostic markers after statistical association of MDRs with clinicopathological features but also dissects genetic interactions and pathways of chromosomal aberrations in tumorigenesis.

Entities:  

Mesh:

Year:  2004        PMID: 15126338     DOI: 10.1158/0008-5472.can-03-2320

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Authors:  Tae-Min Kim; Seon-Hee Yim; Seung-Hun Shin; Hai-Dong Xu; Yu-Chae Jung; Cheol-Keun Park; Jong-Young Choi; Won-Sang Park; Mi-Seon Kwon; Heike Fiegler; Nigel P Carter; Mun-Gan Rhyu; Yeun-Jun Chung
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

Review 2.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  mDia1 targets v-Src to the cell periphery and facilitates cell transformation, tumorigenesis, and invasion.

Authors:  Masahiro Tanji; Toshimasa Ishizaki; Saman Ebrahimi; Yuko Tsuboguchi; Taiko Sukezane; Tsuyoshi Akagi; Margaret C Frame; Nobuo Hashimoto; Susumu Miyamoto; Shuh Narumiya
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

4.  Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population.

Authors:  Subramaniam Mohana Devi; Vellingiri Balachandar; Meyyazhagan Arun; Shanmugam Suresh Kumar; Balasubramanian Balamurali Krishnan; Keshavarao Sasikala
Journal:  Dig Dis Sci       Date:  2012-10-02       Impact factor: 3.199

Review 5.  PTPN13/PTPL1: an important regulator of tumor aggressiveness.

Authors:  Gilles Freiss; Dany Chalbos
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

6.  Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis.

Authors:  Michele Barone; Daniela Spano; Maria D'Apolito; Marta Centra; Carla Lasalandra; Mario Capasso; Alfredo Di Leo; Stefano Volinia; Diego Arcelli; Natalia Rosso; Antonio Francavilla; Claudio Tiribelli; Achille Iolascon
Journal:  Mol Med       Date:  2006 Apr-Jun       Impact factor: 6.354

7.  Single nucleotide polymorphism profiling assay to confirm the identity of human tissues.

Authors:  Ronald Huijsmans; Jan Damen; Hans van der Linden; Mirjam Hermans
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

8.  Identification of Chromosomal Aberrations by Using Trypsin G-banding in Hepatocellular Carcinoma Patients (HCC) in Tamil Nadu, India.

Authors:  Subramaniam Mohana Devi; Vellingiri Balachandar; Palanivel Vel Murugan; Keshavarao Sasikala; Pappusamy Manikantan; Leela Krishnan Venkatakrishnan
Journal:  Trop Life Sci Res       Date:  2010-08

9.  DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.

Authors:  Wen Xue; Alexander Krasnitz; Robert Lucito; Raffaella Sordella; Linda Vanaelst; Carlos Cordon-Cardo; Stephan Singer; Florian Kuehnel; Michael Wigler; Scott Powers; Lars Zender; Scott W Lowe
Journal:  Genes Dev       Date:  2008-06-01       Impact factor: 11.361

10.  Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.

Authors:  Chun-Ming Ho; Kuen-Tyng Lin; Roger Shen; De-Leung Gu; Szu-Shuo Lee; Wen-Hui Su; Yuh-Shan Jou
Journal:  Comput Struct Biotechnol J       Date:  2022-04-09       Impact factor: 6.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.